Compugen Ltd. says it has developed an in silico discovery engine for peptides that bind GPCRs. So far, the engine has yielded eight peptides with dose-dependent activity, and CGEN plans to advance two into preclinical testing before out-licensing them. The company also hopes to partner its discovery technology.

To discover peptide ligands for GPCRs, the company used algorithms to build a virtual model of the peptidome, creating an in silico prediction of peptides most likely to exist based on endogenous cleavage sites in naturally occurring precursor proteins. CGEN's peptidome includes thousands of peptides.